1 report

  • Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma
  • Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals' Oral SYK/JAK Inhibitor Cerdulatinib

It also offers treatments for acid reflux disease, infectious diseases, bipolar I disorder, schizophrenia, alzheimer' s disease, epilepsy, migraine prevention and treatment.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • Portola Pharmaceuticals, Inc.